Previous Device Burden: CGM falling off during exercise, unable to access phone and cannot hear alerts.
Favorite Eversense Benefit: “I don’t worry about wasting a sensor if I’m too sweaty for my CGM to stay on my skin.”
Eversense is designed to overcome the limitations of short-term CGM systems
One Year of Minimal Disruptions2-4
Exceptional Accuracy Over One Year2
Designed for Improved Quality of Life
The Eversense difference.
Eversense is an optimal choice for adults with diabetes on insulin
Eversense helps solve the real-life challenges of traditional CGMs.
If your patients are experiencing:
- Sensors falling or getting knocked off
- Sensors not lasting as long as expected
- Questioning accuracy of readings
- Alarm fatigue
- Skin irritation from adhesives
- False lows or compression lows
See how Eversense outlasts and outperforms traditional CGMs.
Eversense 3652
Short-Term Traditional CGMs3,4
Data Disruptions
Sensor Lifetime
365 days
10-14 days
Survivability Rate at Lifetime Percentage
90%
68.3-80.5%
Accuracy
Compression Lows
Virtually none
Yes
Accuracy in Low Glucose Ranges (MAD in mg/dL)
7.7
14.2-16
Patient Quality of Life
CGM Changes Per Year
1
26-36
Low Glucose Events Detected
(at 60 mg/dL)
(at 60 mg/dL)
91%
76-81%
On Body Vibration Alerts
Yes
No
Removable Smart Transmitter
Yes*
No
Adhesive
Silicone-based
Acrylic-based
The CGM for real life.
Eversense delivers real-life benefits to you and your patients. Download our guide to learn more about the types of patients who benefit most from Eversense.
Getting started is easy.
Step One: Prescribe Eversense
Patient referrals can be made to Ascensia Diabetes Care by:
• Parachute Health
or
• Fax PIF, CMN, Chart Notes and Insurance Info
Step Two: Connect your patient with the Eversense Inserter Network
Our skilled medical professionals will manage:
• Insertion and removal procedures
• Billing
• Scheduling
For patients with Commercial Insurance
Eversense 365 is covered by most commercial health plans.6
Eligible patients may pay as little as $199 for a full year with the Eversense PASS Program†.
1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide.: LBL-6002-01-001 Rev D
2. Senseonics. (2024) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001 Rev A
3. Dexcom (2024) G7 User Manual AW00078-10 Rev 003 MT-00078-10
4. Abbott. (2024) Freestyle Libre 3 Continuous Glucose Monitoring System User Guide ART49385-001 Rev. A 04/24
5. Deiss D., et al. Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 2020, 22(1);48-52. DOI: 10.1089/dia.2019.0159
6. Data on File. Senseonics. Policy Reporter (8/23/2024)
7. Speak to an Eversense Expert for more information on Medicare coverage.
* There is no glucose data generated when the transmitter is removed
† Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility. See website (bit.ly/EversensePass) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. There is a maximum payment of $2,500 per transaction for the program.. There may be instances in which patient out-of-pocket costs exceed what is detailed in the offer. Eversense E3 is not eligible for the PASS Program.
Disclaimer
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0066